Asia-Pacific Acute Myeloid Leukemia Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 338.96 Million |
| Market Size (2029) | USD 517.24 Million |
| CAGR (2024 - 2029) | 6.46 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Asia-Pacific Acute Myeloid Leukemia Treatment Market Analysis
The Asia-Pacific Acute Myeloid Leukemia Treatment Market size is estimated at USD 338.96 million in 2024, and is expected to reach USD 517.24 million by 2029, growing at a CAGR of 6.46% during the forecast period (2024-2029).
Factors such as the high incidence and prevalence of acute myeloid leukemia and advancement in pharmacology and molecular biology to promote drug development in the Asia Pacific region are also anticipated to drive market growth over the forecast period. For instance, according to 'Leukaemia in Australia Statistics 2022', it was estimated that 5,202 new cases of leukemia were likely to be diagnosed in Australia (3,198 males and 2,004 females) in 2022. It was also estimated that a person had a 1 in 58 (or 1.7%) risk of being diagnosed with leukemia by the age of 85 (1 in 47 or 2.1% for males and 1 in 77 or 1.3% for females). Furthermore, government initiatives and funding for AML in the Asia Pacific region are likely to boost market growth.
According to a 2022 update from the Department of Health and Aged Care, from 1st March 2022, Australians with acute myeloid leukemia (AML) were likely to have access to a new treatment option through the Pharmaceutical Benefits Scheme (PBS). Mylotarg (gemtuzumab ozogamicin) was listed for the first time for the treatment of patients with previously untreated de novo CD33-positive AML, for use in combination with standard intensive chemotherapy.
The market is also expected to benefit from continuous developments in pharmacology and molecular biology for the creation of innovative medicines. Pharmaceutical companies competing in the market are investing a lot of money in research programs to develop new solutions. These R&D initiatives are also blamed for the shortcomings of the acute myeloid leukemia medicines now on the market. For instance, in August 2022, Daiichi Sankyo submitted a supplemental New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as continuation monotherapy for the treatment of adult patients in Japan with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).
Thus, the high burden of acute myeloid leukemia advancement in pharmacology and molecular biology and strategic activities by the market players is expected to contribute to the market growth over the forecast period.
Asia-Pacific Acute Myeloid Leukemia Treatment Market Trends
The Chemotherapy Segment is Anticipated to Witness a Growth Over the Forecast Period
Chemotherapy is the main treatment for most people with acute myeloid leukemia (AML). Induction is the first phase of treatment. It is short and intensive, typically lasting about a week. The goal is to clear the blood of leukemia cells (blasts) and to reduce the number of blasts in the bone marrow to normal. Consolidation is chemo given after the patient has recovered from induction. It is meant to kill the small number of leukemia cells that are still around but can't be seen (because there are so few of them).
The chemotherapy segment is likely to witness growth over the forecast period owing to the factors such as the high incidence and prevalence of acute myeloid leukemia and advancement in pharmacology and molecular biology to promote drug development for AML. For instance, as per a 2022 update from National Cancer Center Japan, the estimated number of leukemia cases in Japan was 14,700 in 2022. A rise in cases of leukemia and AML is likely to increase the demand for therapeutics, thereby boosting market growth over the forecast period.
Another article published in June 2022 in PubMed stated that the establishment of the Alan Walker Cancer Care Centre (AWCCC) at Royal Darwin Hospital, Northern Territory (NT) of Australia, provides radiotherapy, chemotherapy, and other specialist cancer services and its investment in a PET Scanner has reduced patients' need to travel interstate for cancer diagnosis and treatment. The new chemotherapy day units at Alice Springs Hospital and Katherine Hospital and the rapid expansion of tele-oncology have also reduced patient travel within the NT. Such amenities providing chemotherapy have increased the acceptance and adoption of chemotherapy for AML treatment, which is anticipated to drive the market over the forecast period.
Thus, growing prevalence of acute myeloid leukemia and growing adoption of chemotherapy is expected to contribute in the segment growth over the forecast period.
China is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
China is expected to hold a significant market share due to increasing incidences of blood cancer and advancement in pharmacology and molecular biology to promote drug development. Moreover, R&D expenditure in healthcare (oncology) is also anticipated to propel the growth of the market in China. Moreover, the application of targeted therapy and stem cell transplant for acute myeloid leukemia is expected to drive the market in the country. For instance, as per an article published in October 2022 in PLOS ONE, chronic myeloid leukemia (CML), a myeloproliferative blood cancer, had an incidence of 0.39-0.55 cases per 100,000 adults in China.
Furthermore, product launches, the presence of key players, collaborations, and mergers within organizations relating to AML treatment in China are anticipated to boost market growth over the forecast period. For instance, in January 2022, CStone received new drug approval for China's first IDH1 inhibitor, TIBSOVO (ivosidenib tablets), as a new precision therapy for patients with acute myeloid leukemia. Furthermore, in May 2024, HUTCHMED (China) Limited has commenced a Phase III clinical trial for HMPL-306, targeting patients in China with relapsed or refractory acute myeloid leukemia (AML) and mutated isocitrate dehydrogenase (“IDH”) 1 or 2. The trial marks a significant step in the company's pursuit of advanced AML treatments. On May 11, 2024, the trial saw its inaugural patient receiving the initial dose.
Thus, high burden of acute myeloid leukemia and strategic activities by the market players is expected to boost the growth of the studied market in region over the forecast period.
Asia-Pacific Acute Myeloid Leukemia Treatment Industry Overview
The market for acute myeloid leukemia treatment in the Asia-Pacific is semi-consolidated and comprises global players. Some of the key players in this market are Novartis AG, Pfizer Inc., Teva Pharmaceuticals, and AbbVie Inc., among others. With the rising focus of pharmaceutical companies to provide better therapeutics for cancer, it is believed that more companies will penetrate the market in the near future.
Asia-Pacific Acute Myeloid Leukemia Treatment Market Leaders
-
AbbVie Inc.
-
Pfizer Inc.
-
Teva Pharmaceutical
-
Sun Pharmaceutical Industries Ltd
-
Novartis AG
*Disclaimer: Major Players sorted in no particular order
Asia-Pacific Acute Myeloid Leukemia Treatment Market News
- May 2024 : Nippon Shinyaku Co., Ltd. introduced Vyxeos Combination, an I.V. injection (comprising Daunorubicin hydrochloride and cytarabine in a liposomal formulation), specifically targeting high-risk acute myeloid leukemia (AML) patients in Japan.
- March 2024: Novartis India, the Indian subsidiary of the Swiss pharmaceutical powerhouse Novartis AG, secured a distribution partner for the upcoming launch of Asciminib designed to combat chronic myeloid leukemia (CML) by specifically targeting the ABL myristoyl pocket (STAMP).
Asia-Pacific Acute Myeloid Leukemia Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
4.3 Market Restraints
4.3.1 Complications Related to Chemotherapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Therapy
5.1.1 Chemotherapy
5.1.1.1 Anthracycline Drugs
5.1.1.2 Alkylating Agents
5.1.1.3 Anti-metabolites
5.1.1.4 Other Chemotherapies
5.1.2 Targeted Therapy
5.1.3 Stem Cell Transplant
5.1.4 Other Therapies
5.2 Geography
5.2.1 China
5.2.2 Japan
5.2.3 India
5.2.4 Australia
5.2.5 South Korea
5.2.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astellas Pharma Inc.
6.1.2 AbbVie Inc.
6.1.3 Celgene Corporation
6.1.4 Daiichi Sankyo Company Limited
6.1.5 Novartis AG
6.1.6 Pfizer Inc.
6.1.7 Teva Pharmaceutical Industries Ltd
6.1.8 Viatris (Mylan NV)
6.1.9 Sun Pharmaceutical Industries Ltd
6.1.10 Fresenius SE & Co. KGaA
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Asia-Pacific Acute Myeloid Leukemia Treatment Industry Segmentation
As per the scope of the report, acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells, which get collected in the bone marrow and disturb the production of normal blood cells.
The Asia-Pacific acute myeloid leukemia treatment market is segmented by therapy and geography. By Therapy the market is segmented as chemotherapy targeted therapy, stem cell transplant, and other therapies. By geography, the market is segmented as China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific. The report offers the value (in USD) for the above segments.
| By Therapy | ||||||
| ||||||
| Targeted Therapy | ||||||
| Stem Cell Transplant | ||||||
| Other Therapies |
| Geography | |
| China | |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific |
Asia-Pacific Acute Myeloid Leukemia Treatment Market Research FAQs
How big is the Asia-Pacific Acute Myeloid Leukemia Treatment Market?
The Asia-Pacific Acute Myeloid Leukemia Treatment Market size is expected to reach USD 338.96 million in 2024 and grow at a CAGR of 6.46% to reach USD 517.24 million by 2029.
What is the current Asia-Pacific Acute Myeloid Leukemia Treatment Market size?
In 2024, the Asia-Pacific Acute Myeloid Leukemia Treatment Market size is expected to reach USD 338.96 million.
Who are the key players in Asia-Pacific Acute Myeloid Leukemia Treatment Market?
AbbVie Inc., Pfizer Inc., Teva Pharmaceutical, Sun Pharmaceutical Industries Ltd and Novartis AG are the major companies operating in the Asia-Pacific Acute Myeloid Leukemia Treatment Market.
What years does this Asia-Pacific Acute Myeloid Leukemia Treatment Market cover, and what was the market size in 2023?
In 2023, the Asia-Pacific Acute Myeloid Leukemia Treatment Market size was estimated at USD 317.06 million. The report covers the Asia-Pacific Acute Myeloid Leukemia Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Acute Myeloid Leukemia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
APAC Acute Myeloid Leukemia Treatment Industry Report
Statistics for the 2024 APAC Acute Myeloid Leukemia Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. APAC Acute Myeloid Leukemia Treatment analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
